
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …
Alnylam will cut 33% of its workforce this year as it looks to focus on developing its own products. The …

The emerging field of RNA interference – also known as ‘gene silencing’ – is one of the most promising in …
A new MicroRNA treatment for prostate cancer has been highly effective against the disease in pre-clinical studies. MicroRNAs, or miRNAs, …
Novartis has joined the race to develop a ‘gene silencing’ treatment by signing a new deal with siRNA specialist Quark …
Jorg Kaufmann has been made vice president of research at UK biotech company Silence Therapeutics. He previously served as senior …
US researchers have shown that a targeted nanoparticle can penetrate cancer cells in order to deliver small interfering RNAs (siRNAs), …
Coronado Biosciences’ cancer treatment effective in animal modelsCoronado Biosciences has reported that the Bcl-2 inhibitor, apogossypol, effectively killed a variety …

